Cancer Research Landon Prizes for Basic and Translational Cancer Research  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sawai, H.
Right arrow Articles by Eibl, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sawai, H.
Right arrow Articles by Eibl, G.
[Cancer Research 65, 11536-11544, December 15, 2005]
© 2005 American Association for Cancer Research


Cell and Tumor Biology

The G691S RET Polymorphism Increases Glial Cell Line–Derived Neurotrophic Factor–Induced Pancreatic Cancer Cell Invasion by Amplifying Mitogen-Activated Protein Kinase Signaling

Hirozumi Sawai1, Yuji Okada1, Kevork Kazanjian1, Joseph Kim2, Sascha Hasan1, Oscar J. Hines1, Howard A. Reber1, Dave S.B. Hoon2 and Guido Eibl1

1 Hirshberg Laboratories for Pancreatic Cancer Research, Department of Surgery, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California and 2 Martin H. Weil Research Laboratories, Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California

Requests for reprints: Guido Eibl, Department of Surgery, David Geffen School of Medicine, University of California at Los Angeles, 675 Charles E. Young Drive South, MRL 2535, Los Angeles, CA 90095. Phone: 310-794-9577; Fax: 310-825-8975; E-mail: Geibl{at}mednet.ucla.edu.

Mutations of the RET proto-oncogene are responsible for several inherited human diseases and may function as genetic modifiers of the disease. However, the role of RET mutations in pancreatic cancer has not been studied. Expression of the glial cell line–derived neurotrophic factor (GDNF) receptors RET and GDNF family receptor {alpha}1 (GFR{alpha}1) in human pancreatic cancer cells was determined by Western blot, immunofluorescence, and flow cytometry. The effect of GDNF on cell proliferation and invasion was assessed. Small interfering RNA and antibodies were used to evaluate the involvement of RET. The G691S RET polymorphism was analyzed by sequencing and restriction analysis. The modifying effect of G691S RET on GDNF-induced invasion and mitogen-activated protein kinase (MAPK) signaling was evaluated. Transfection studies with wild-type and mutated RET determined the functional role of the G691S polymorphism. Pancreatic cancer specimens and matched tissues were analyzed for the presence of the G691S RET polymorphism. GDNF receptors were found on all cell lines. GDNF increased pancreatic cancer cell proliferation and invasion, which was mediated by RET. The effect of GDNF was more profound in cells with the G691S RET polymorphism (P < 0.01). G691S RET correlated with an enhanced activation of the downstream extracellular signal-regulated kinase pathway. Overexpression of G691S RET increased pancreatic cancer cell invasion. The G691S RET polymorphism was also detected in human pancreatic tumors and represented a somatic mutation in some patients. These findings indicate that the G691S RET single nucleotide polymorphism may directly correlate with the aggressive growth of pancreatic cancers and may function as a genetic modifier or even low-penetrance gene. (Cancer Res 2005; 65(24): 11536-44)




This article has been cited by other articles:


Home page
Cancer Res.Home page
A. Boulay, M. Breuleux, C. Stephan, C. Fux, C. Brisken, M. Fiche, M. Wartmann, M. Stumm, H. A. Lane, and N. E. Hynes
The Ret Receptor Tyrosine Kinase Pathway Functionally Interacts with the ER{alpha} Pathway in Breast Cancer
Cancer Res., May 15, 2008; 68(10): 3743 - 3751.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Vidal, S. Warner, R. Read, and R. L. Cagan
Differing Src Signaling Levels Have Distinct Outcomes in Drosophila
Cancer Res., November 1, 2007; 67(21): 10278 - 10285.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
O. Oppenheimer, N.-K. Cheung, and W. L. Gerald
The RET oncogene is a critical component of transcriptional programs associated with retinoic acid-induced differentiation in neuroblastoma
Mol. Cancer Ther., April 1, 2007; 6(4): 1300 - 1309.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
I. Plaza-Menacho, T. van der Sluis, H. Hollema, O. Gimm, C. H. C. M. Buys, A. I. Magee, C. M. Isacke, R. M. W. Hofstra, and B. J. L. Eggen
Ras/ERK1/2-mediated STAT3 Ser727 Phosphorylation by Familial Medullary Thyroid Carcinoma-associated RET Mutants Induces Full Activation of STAT3 and Is Required for c-fos Promoter Activation, Cell Mitogenicity, and Transformation
J. Biol. Chem., March 2, 2007; 282(9): 6415 - 6424.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.